179 related articles for article (PubMed ID: 34989284)
21. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.
Park JY; Nam JH
Oncologist; 2015 Mar; 20(3):270-8. PubMed ID: 25673106
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
23. Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review.
Raffone A; Travaglino A; Saccone G; Alviggi C; Mascolo M; De Placido G; Insabato L; Mollo A; Zullo F
Acta Obstet Gynecol Scand; 2019 Jul; 98(7):842-855. PubMed ID: 30714089
[TBL] [Abstract][Full Text] [Related]
24. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
Shikeli S; Gowri V; Rawahi TA
JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
[TBL] [Abstract][Full Text] [Related]
25. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.
Uccella S; Zorzato PC; Dababou S; Bosco M; Torella M; Braga A; Frigerio M; Gardella B; Cianci S; Laganà AS; Franchi MP; Garzon S
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143933
[TBL] [Abstract][Full Text] [Related]
26. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
27. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
28. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gunderson CC; Fader AN; Carson KA; Bristow RE
Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
[TBL] [Abstract][Full Text] [Related]
29. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
30. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
31. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.
Shan BE; Ren YL; Sun JM; Tu XY; Jiang ZX; Ju XZ; Zang RY; Wang HY
Arch Gynecol Obstet; 2013 Nov; 288(5):1115-23. PubMed ID: 23644919
[TBL] [Abstract][Full Text] [Related]
33. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
34. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
[TBL] [Abstract][Full Text] [Related]
35. Updates on Conservative Management of Endometrial Cancer.
Corzo C; Barrientos Santillan N; Westin SN; Ramirez PT
J Minim Invasive Gynecol; 2018 Feb; 25(2):308-313. PubMed ID: 28782618
[TBL] [Abstract][Full Text] [Related]
36. Fertility-sparing treatment in women with endometrial cancer.
Won S; Kim MK; Seong SJ
Clin Exp Reprod Med; 2020 Dec; 47(4):237-244. PubMed ID: 33181010
[TBL] [Abstract][Full Text] [Related]
37. Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives.
Vitale SG; Riemma G; Carugno J; Chiofalo B; Vilos GA; Cianci S; Budak MS; Lasmar BP; Raffone A; Kahramanoglu I
Transl Cancer Res; 2020 Dec; 9(12):7767-7777. PubMed ID: 35117379
[TBL] [Abstract][Full Text] [Related]
38. Endometrial cancer.
Arora V; Quinn MA
Best Pract Res Clin Obstet Gynaecol; 2012 Jun; 26(3):311-24. PubMed ID: 22277287
[TBL] [Abstract][Full Text] [Related]
39. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis.
Fan Z; Li H; Hu R; Liu Y; Liu X; Gu L
Int J Gynecol Cancer; 2018 Feb; 28(2):385-393. PubMed ID: 29266019
[TBL] [Abstract][Full Text] [Related]
40. Role of hysteroscopy during conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer in patients who desire pregnancy.
Gil González Y; Pérez Morales ME; Emergi Zhrigen Y; Santana Suárez MA; Pérez Matos C; Nieto Naya MÁ; Ocón Padrón L; Laseca Modrego M; Arencibia Sánchez O; Sánchez Sánchez V; Martín Martínez AI
J Obstet Gynaecol; 2022 Nov; 42(8):3435-3440. PubMed ID: 37017372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
